Doctors and nurses—many of whom are also researchers—are working around the clock at UCHealth University of Colorado Hospital (UCH) to treat patients who are hospitalized with COVID-19. Over the next several months, research teams and caregivers will treat patients using four different drugs in the course of multiple clinical trials using Sarilumab, Remdesivir and Hydroxychloroquine.
Dr. Joaquin Espinosa, professor of pharmacology in the CU School of Medicine is the force behind a strategic and coordinated effort to bring $16.5 million in grant funding to CU for Down syndrome research.
The CCTSI is pleased to announce a change in two key leadership roles: Bethany Kwan, PhD, MSPH will assume the role of Director of Dissemination & Implementation Research. Cathy Bodine, PhD will serve as the Director of the Innovation Ecosystem.
In the fall of 2019, the FDA approved a new breakthrough therapy for cystic fibrosis (CF), a genetic disease that leads to lung, digestive, endocrine and nutritional problems. Researchers from Children’s Hospital Colorado were part of a national network that oversaw clinical trials leading to the approval of TRIKAFTA, a highly-effective treatment for people with CF, 12 years of age and older. The trials have taken place in the CCTSI’s pediatric Clinical and Translational Research Center (CTRC) at Children’s Colorado.